Saving money, worry, and time: A possible test for ruling out preeclampsia
Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: secondary analysis of the Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia
A study in 2019 found that the level of two molecules in the blood of pregnant women (called the “s-Flt-1/PlGF ratio”) can help rule out suspected preeclampsia within 4 weeks of disease. Researchers for this study asked if this ratio worked to help rule out preeclampsia in a real-world setting. Researchers used data from a study called INSPIRE (“Interventional Study on Prediction of Preeclampsia-Eclampsia” trial) and calculated this ratio among women in the study who did and did not develop preeclampsia. The researchers found a strong negative predictive value of 97% for the ratio value to rule of preeclampsia; meaning among those women who had a “negative” ratio score, the probability of not developing preeclampsia was 97%.
Take home message: There is validity and value in using the sFLT-1/PlGF ratio for women that have suspected preeclampsia to reduce the costs, patient anxiety, and inconvenience that comes with unnecessary hospital admission or repeated follow ups with healthcare providers.
Link: https://reader.elsevier.com/reader/sd/pii/S0002937821025436?token=DCC29D3A73A9F46F156087C712A52785416B
About Research Roundup
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, MD Jenny Sones, PhD, DVM, and Robin Trupp, PhD, RN.
Related Articles
1777566412.png)
Placental dysfunction can result in conditions such as preeclampsia, which have traditionally been managed with close monitoring and appropriately timed delivery. There is currently no cure for preecl...
1777563523.png)
Gestational hypertension continues to be a growing public health concern contributing to maternal morbidity, mortality, and long-term health complications in the U.S. While changes in vision—suc...
1777562643.png)
Background Low-dose aspirin (81 mg) is a treatment known to help lower the risk of preeclampsia. However, not everyone who is at higher risk is told to take it. This study looks at whether a screening...
Women who experienced Preeclampsia have a higher lifetime risk of developing cardiovascular disease (CVD) than women who did not suffer from this pregnancy complication. Researchers wanted to know if...
Recent findings in preeclampsia research have shown that preeclampsia likely has at least two variants – an early onset and a late onset variant. Early onset is typically defined as before 34 we...